Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Rheumatology

  • Article

    SGLT-2 inhibitors May Decrease Recurrent Gout Flares in Patients with Type 2 diabetes

    May 1, 2024

    Dr. Bernal Clinical question: Do SGLT-2 inhibitors decrease gout flares in patients with type 2 diabetes and a known history of gout? Background: Sodium–glucose cotransporter-2 inhibitors...

  • News

    Rituximab likely raises risk of hospital death in COVID-19 patients

    December 2, 2021

    In a retrospective study of hospitalized COVID-19 patients, “only 1 of 303 drugs examined, rituximab, was associated with an increased risk of in-hospital death ... both when used for rheumatologic as well as for cancer therapy.”

  • News

    ‘Misleading’ results in colchicine COVID-19 trials meta-analysis

    November 23, 2021

    “While the small studies are potentially insight providing, the large studies are the only ones worth giving our attention to in the context of the meta-analysis.”

  • 1
    News

    Two swings, two misses with colchicine, Vascepa in COVID-19

    September 1, 2021

    The study cohorts varied from healthcare and public workers at high risk for infection to individuals already hospitalized with COVID-19.

  • News

    Tocilizumab shortage continues as pandemic wears on

    August 19, 2021

    Emergency use authorization of tocilizumab for COVID-19 has led to a global shortage, but supplies for rheumatoid arthritis and other inflammatory conditions are faring better – for now.

  • News

    Patients with rheumatic disease may experience flares after SARS-CoV-2 vaccination

    June 28, 2021

    A total of 202 SRD flares were reported by 165 patients (14.9%).

  • 1
    News

    Mavrilimumab may aid severe COVID-19 recovery

    June 10, 2021

    The granulocyte/macrophage-colony stimulating factor (GM-CSF) blocker reduced the need for mechanical ventilation and death by day 29 versus placebo.

  • 1
    News

    Hypertension worsened by commonly used prescription meds

    May 6, 2021

    Close to 20% of U.S. adults with hypertension are on a prescription drug, such as NSAIDs, known to raise blood pressure, creating an opportunity for drug substitution.

  • News

    Psoriasis associated with an increased risk of COVID-19 in real-world study

    April 28, 2021

    Those treated with TNF-alpha inhibitors, methotrexate, and apremilast had statistically lower risks of COVID-19 vs. those on topical therapy.

  • 1
    News

    Arthritis drug may curb myocardial damage in acute STEMI

    April 13, 2021

    Tocilizumab appears to improve myocardial salvage by helping tamp down the inflammatory overshoot that occurs during infarction and reperfusion.

1 2 3 … 7Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences